immun
system
aweinspir
control
structur
maintain
delic
constantli
chang
balanc
proimmun
function
fight
infect
cancer
regulatori
suppress
function
involv
immun
toler
homeostat
rest
state
activ
determin
integr
signal
space
time
thu
improv
control
densiti
combin
durat
immun
signal
deliv
central
goal
better
combat
infecti
diseas
cancer
autoimmun
selfassembl
present
uniqu
opportun
synthes
materi
welldefin
composit
control
physic
arrang
molecular
build
block
review
highlight
strategi
exploit
capabl
improv
understand
preciselydisplay
cue
interact
immun
cell
tissu
present
work
center
fundament
properti
regul
natur
magnitud
immun
respons
highlight
preclin
clinic
applic
selfassembl
technolog
vaccin
cancer
autoimmun
describ
key
manufactur
regulatori
hurdl
face
area
vaccin
transform
technolog
enabl
activ
immun
system
recogn
destroy
specif
pathogen
support
near
erad
diseas
polio
small
pox
even
potenti
engin
immun
function
far
richer
vaccin
alon
immun
system
exquisit
complex
control
system
mean
activ
respons
combat
pathogen
rather
dynam
balanc
exist
proimmuneinflammatori
process
regulatorysuppress
function
homeostat
ie
rest
activ
level
fig
vaccin
common
goal
induc
specif
longlast
adapt
respons
foreign
pathogen
futur
protect
infect
ie
immunolog
memori
cancer
immunotherapi
one
object
gener
fastact
killer
cell
destroy
exist
tumor
yet
combat
autoimmun
diseas
immun
system
malfunct
attack
healthi
tissu
therapi
may
seek
turn
suppress
particular
aspect
inflammatori
respons
thu
great
interest
better
understand
interplay
activ
rest
regulatori
immun
function
har
knowledg
could
help
overcom
diverg
hurdl
continu
persist
infecti
diseas
cancer
autoimmun
exampl
hiv
undergo
rapid
mutat
evad
immun
recognit
clearanc
cancer
cell
secret
suppress
signal
activ
subdu
antitumor
immun
autoimmun
diseas
multipl
sclerosi
diabet
defect
immun
checkpoint
lead
inflamm
destruct
selfcel
tissu
nuanc
highlight
idea
overcom
exist
emerg
challeng
public
health
requir
gener
immun
function
control
specif
characterist
immun
respons
idea
term
immunomodul
immun
system
natur
govern
function
integr
rel
concentr
kinet
antigenspeptid
fragment
pathogen
determin
target
immun
responsealong
immun
cue
rang
nucleic
acid
signal
protein
call
cytokin
small
molecul
ligand
drug
multidisciplinari
strategi
bring
togeth
immunolog
translat
perspect
engin
technolog
vital
continu
decod
better
direct
interact
particular
materi
allow
precis
control
signal
encount
densiti
valenc
examplecan
reveal
new
knowledg
immun
cell
detect
engag
pathogen
vaccin
similarli
system
molecularscal
control
present
multipl
signal
offer
opportun
exploit
direct
function
codeliveri
demand
greater
spatial
tempor
control
increas
complex
candid
vaccin
immunotherapi
yet
across
fundament
research
preclin
develop
translat
human
need
vaccin
immunotherapi
well
defin
character
remain
constant
latter
point
increas
challeng
manufactur
regulatori
perspect
emerg
technolog
enabl
ration
tunabl
welldefin
natur
discuss
selfassembl
review
discuss
uniqu
featur
selfassembl
mean
studi
immun
function
enhanc
immunosens
diagnost
improv
vaccin
immunotherapi
deliveri
technolog
begin
brief
background
immun
system
characterist
selfassembl
materi
describ
key
exampl
recent
literatur
highlight
uniqu
advantag
selfassembl
exploit
probe
control
immun
function
throughout
review
emphas
new
way
selfassembl
might
appli
current
clinic
challeng
well
hurdl
self
fig
immun
system
oper
dynam
mix
mainten
process
proimmun
function
tolerogen
function
balanc
function
dictat
antigenpres
cell
dendrit
cell
dc
encount
antigen
integr
inflammatori
regulatori
signal
present
local
microenviron
exampl
infect
inflammatori
diseas
dc
detect
antigen
presenc
inflammatori
danger
signal
drive
expans
effector
cell
eff
trigger
antibodi
respons
contrast
toler
detect
antigen
presenc
regulatori
environ
lead
expans
regulatori
cell
reg
induct
anerg
cell
delet
cell
typic
follow
perturb
skew
immun
functionsuch
infect
administr
vaccineth
immun
system
return
rest
homeostat
state
assembl
might
help
tackl
viewpoint
manufactur
regulatori
process
profession
antigen
present
cell
apc
immun
system
activ
survey
tissu
throughout
bodi
verifi
ident
healthi
self
molecul
cell
tissu
process
prevent
incorrect
attack
sampl
display
selfantigen
absenc
stimulatori
immun
cue
seri
regulatori
mechan
also
help
maintain
toler
occur
develop
other
ongo
throughout
life
simultan
apc
sens
cue
surround
environ
inflammatori
cytokin
presenc
danger
signal
common
invad
pathogen
apc
dendrit
cell
dc
integr
signal
control
cytokin
secret
express
level
surfac
protein
lead
matur
activ
inform
relay
recruit
cell
innat
immun
system
secret
chemic
signal
ie
chemokin
cytokin
ii
interact
cell
adapt
immun
system
tissu
coordin
immun
lymph
node
ln
innat
immun
function
engulf
bacteria
trigger
inflammatori
immun
cell
recruit
occur
minut
hour
less
specif
provid
immunolog
memori
contrast
adapt
respons
pathogen
eg
virus
bacteria
develop
day
week
month
drive
molecularlyspecif
destruct
neutral
pathogen
lead
immun
memori
last
decad
longer
lymphocyt
cell
b
cell
major
player
exert
function
effect
adapt
immun
cell
express
surfac
receptor
bind
target
cognat
antigen
peptid
moieti
particular
cell
develop
specif
upon
recognit
cognat
antigen
present
major
histocompat
protein
complex
mhc
apc
lymphocyt
bind
antigen
display
call
signal
fig
case
intracellular
antigen
display
cell
infect
viru
present
occur
via
mhci
pathway
drive
expans
cytotox
cell
directli
kill
target
cell
contrast
extracellular
antigen
engulfedfrag
bacteria
examplear
present
via
mhcii
pathway
expand
helper
cell
importantli
simultan
lymphocyt
receiv
cue
guid
prolifer
differenti
enabl
particular
b
cell
function
instanc
costimulatori
marker
express
differ
level
surfac
apc
engag
receptor
lymphocyt
cellcel
interact
exampl
signal
combin
cytokin
present
local
cell
environ
consid
signal
togeth
signal
bia
lymphocyt
develop
toward
specif
function
cell
cognat
antigen
may
differenti
toward
either
proinflammatori
tolerogen
phenotyp
fig
helper
cell
interact
b
cell
work
apc
drive
b
cell
matur
secret
high
affin
antibodi
neutral
extracellular
toxin
tag
extracellular
pathogen
destruct
b
cell
activ
share
featur
differ
exist
ultim
determin
strongli
antibodi
b
cell
secret
bind
pathogen
featur
molecul
exhibit
exampl
dimer
transport
mucos
membran
select
exploit
activ
rest
suppress
immun
mechan
critic
goal
new
vaccin
immunotherapi
potenti
promot
cellmedi
ie
celldriven
immun
continu
particularli
advantag
viral
diseas
cancer
case
viral
antigen
antigen
overexpress
tumor
cell
target
killer
cell
case
aris
natur
other
via
cell
engin
infus
cancer
patient
contrast
potenti
control
phenotyp
cell
may
vital
capabl
promot
toler
autoimmun
diseas
multipl
sclerosi
h
h
cell
specif
recogn
compon
myelinth
matrix
insul
protect
neuronsdr
inflamm
diseas
attack
myelin
capac
instead
expand
myelinrecogn
cell
toward
regulatori
cell
eg
reg
could
enabl
myelinspecif
control
diseas
without
broad
immunosuppress
effect
associ
current
clinic
therapi
similarli
regul
metabol
function
away
state
extrem
activ
suppress
toward
moder
homeostat
level
might
help
address
diseas
caus
system
chronic
inflamm
result
loss
immun
toler
thu
elicit
better
control
interact
immun
cell
ultim
immun
function
core
theme
field
focu
selfassembl
materi
offer
uniqu
opportun
contribut
vision
biomateri
emerg
promis
technolog
enhanc
spatial
tempor
control
immun
signal
display
deliveri
broadli
biomateri
offer
attract
properti
deliveri
multipl
class
cargo
cell
tissu
target
protect
payload
enzymat
degrad
increas
circul
time
defin
deliveri
kinet
howev
signific
challeng
continu
limit
materi
clinic
use
exampl
ineffici
load
immunolog
cargo
carrier
heterogen
size
distribut
lack
control
physic
arrang
molecul
low
frequenc
success
biomateri
clinic
past
decad
reveal
need
critic
assess
translat
biomateri
research
stringent
model
ensur
clinicallyrelev
question
pathway
target
complex
mani
materi
approach
also
add
hurdl
technolog
aim
human
use
difficulti
manufactur
character
approv
system
much
greater
rel
drug
antibodi
therapi
dispar
part
due
histor
experi
manufactur
regul
drug
antibodi
lastli
need
better
definit
control
particularli
import
applic
target
immun
system
signal
pathway
control
dynam
equilibrium
within
realm
biomateri
selfassembl
materi
repres
uniqu
opportun
gener
wellcontrol
structur
divers
array
molecular
build
block
includ
peptid
nucleic
acid
lipid
synthet
polym
fig
center
defin
selfassembl
spontan
interact
molecul
driven
convers
entropicallyfavor
state
process
occur
nano
micro
macroscal
via
noncoval
forc
electrostat
hydrophob
interact
owe
spontan
natur
selfassembl
materi
often
gener
low
energi
input
temperatur
ph
valu
physiolog
rang
characterist
gener
compat
inher
less
stabl
biolog
build
block
sever
type
selfassembl
materi
immun
engin
field
use
modifi
surfac
twoor
threedimension
surfac
eg
spheric
particl
complex
microor
nanoscal
topographi
directli
gener
structur
particul
materi
three
emerg
class
materi
describ
noncoval
interact
drive
selfassembl
fig
center
first
hydrophob
amphiphil
molecul
often
assembl
hydrophob
interact
micel
liposom
elong
fibrillik
structur
exampl
lipid
inher
amphiphil
make
molecul
wellsuit
hydrophob
interactionbas
assembl
peptid
design
incorpor
motif
fold
secondari
structur
eg
alpha
helic
beta
sheet
provid
hierarch
organ
second
electrostat
interact
drive
associ
peptid
charg
residu
nucleic
acid
synthet
polym
charg
molecul
drive
forc
har
condens
complex
build
block
nanoparticl
microparticl
well
drive
programm
layerbylay
assembl
polyelectrolyt
multilay
final
nucleic
acid
design
base
complementar
promot
fold
assembl
predict
welldefin
structur
broadli
speak
type
selfassembl
materi
tap
applic
rang
optic
energi
drug
deliveri
recent
immunolog
vaccin
immunotherapi
describ
recent
literatur
demonstr
transform
potenti
selfassembl
offer
engin
immun
function
depict
fig
focu
four
area
har
selfassembl
tool
interrog
fundament
aspect
immun
respons
ii
immun
sens
diagnost
iii
gener
design
guidelin
new
vaccin
immunotherapi
deliveri
strategi
iv
applic
aim
clinic
translat
span
infecti
diseas
cancer
autoimmun
also
integr
discuss
increas
import
consid
manufactur
regulatori
requir
new
vaccin
immunotherapi
even
preclin
design
stage
fig
bottom
review
center
selfassembl
new
innov
materi
scienc
immunolog
engin
also
pois
gener
enabl
new
capabl
immun
engin
field
evid
simpli
examin
divers
bodi
excit
work
compris
special
issu
new
aspect
immunolog
selfassembl
appli
deciph
fundament
characterist
immun
respons
understand
provid
new
basic
knowledg
inform
design
better
vaccin
immunotherapi
carrier
technolog
import
exampl
use
viruslik
particl
vlp
vlp
recombin
protein
design
selfassembl
particul
structur
express
cell
cultur
system
eg
yeast
bacteria
plant
cell
engin
produc
sequenc
interest
particl
mimic
nativ
virus
replic
therefor
pose
lower
safeti
risk
compar
live
attenu
vaccin
vlp
current
use
clinicallyapprov
vaccin
protect
human
human
papillomaviru
hpv
hepat
b
viru
hbv
clinic
use
highlight
key
advantag
vlp
present
set
antigen
physic
conform
found
nativ
pathogen
maxim
immunogen
contrast
mani
approach
conform
antigen
either
poorli
control
may
result
consist
arrang
antigen
one
differ
space
geometri
shape
nativ
pathogen
dispar
synthet
platform
target
pathogen
result
poor
immunogen
efficaci
despit
advantag
vlp
limit
exist
vlp
clinic
combin
antigen
deliv
welldefin
wellcontrol
instead
fragment
pathogen
isol
express
recombin
system
eg
bacteri
cell
screen
immunogen
potenti
approach
identifi
approv
vaccin
promis
candid
potenti
program
combin
antigen
display
without
sacrif
immunogen
could
gener
strong
respons
greater
select
effici
vlp
also
motiv
work
har
specif
structur
moieti
rationallydesign
synthet
system
well
defin
formul
specif
antigen
respons
gener
exampl
context
hiv
synthet
nanoparticl
use
tool
interrog
role
selfassembl
exhibit
uniqu
featur
har
program
assembl
divers
array
macromolecul
noncoval
interact
regul
selfassembl
includ
hydrophob
interact
hydrogen
bond
electrostat
interact
dna
rna
hybrid
exploit
design
materi
programm
physiochem
characterist
insid
circl
interact
materi
cell
tissu
immun
system
interrog
gener
design
rule
could
inform
develop
new
vaccin
immunotherapi
top
left
parallel
selfassembl
materi
employ
develop
new
platform
technolog
immun
sens
diagnost
applic
bottom
left
final
potenti
selfassembl
biomateri
program
magnitud
natur
immun
respons
bottom
right
well
efficaci
model
infecti
diseas
cancer
autoimmun
transplant
studi
explor
clinic
potenti
emerg
selfassembl
technolog
top
right
endeavor
creat
feedback
loop
inform
one
anoth
lastli
feasibl
requir
manufactur
need
consid
earli
design
develop
process
bottom
antigen
conform
valenc
studi
motiv
recent
report
reveal
portion
hiv
envelop
glycoprotein
coat
viral
capsida
trimer
compos
three
monomersi
critic
recognit
hiv
immun
system
colleagu
hypothes
use
nanoparticl
could
enabl
surfac
display
trimer
high
densiti
fig
report
compar
bind
affin
nanoparticledisplay
trimer
free
ie
nanoparticlefre
monom
use
two
wellcharacter
antibodi
test
antibodi
recogn
monom
either
monom
trimer
form
reveal
low
affin
bind
monom
fig
top
left
higher
affin
bind
nanoparticledisplay
trimer
fig
top
right
indic
dramat
decreas
dissoci
constant
k
next
antibodi
previous
shown
bind
nativ
trimer
test
expect
free
monom
bind
trimerspecif
antibodi
fig
bottom
left
nanoparticl
assembl
drove
high
affin
bind
fig
bottom
right
result
confirm
nanoparticl
display
interfer
physic
conform
trimer
rather
enabl
rapid
recognit
bind
antibodi
high
densiti
present
trimer
case
demonstr
concret
advantag
selfassemblyen
approach
potenti
mimic
viral
surfac
present
specif
antigen
investig
role
physic
arrang
engag
interact
biolog
molecul
like
antibodi
research
focus
understand
display
antigen
higher
order
structur
selfassembl
particl
also
use
understand
vlp
assembl
exampl
link
amino
acid
sequenc
integr
mechan
properti
vlp
investig
studi
author
introduc
amino
acid
point
mutat
monom
minut
viru
mice
viru
wellcharacter
structur
sever
mutat
partial
complet
inhibit
spontan
assembl
vlp
result
underscor
vital
role
nativ
noncoval
interact
sidechain
amino
acid
monom
drive
selfassembl
formul
maintain
potenti
assembl
spontan
vlp
atom
forc
microscopi
studi
gener
reveal
increas
stiff
sequenc
mutat
stiff
physiochem
properti
shown
impact
cell
activ
prolifer
thu
futur
studi
elucid
role
vlp
properti
influenc
immunomodulatori
function
well
comparison
vlp
synthet
carrier
eg
polym
emuls
micel
polymernucl
acid
complex
could
inform
design
materi
specif
mechan
properti
tune
respons
translat
applic
broadli
speak
immunosens
requir
detect
rare
antigen
antibodi
immun
cell
among
complex
heterogen
biolog
sampl
eg
patient
blood
serum
diagnos
patient
inform
therapeut
intervent
thu
interest
develop
strategi
enhanc
specif
sensit
detect
screen
platform
knowledg
import
vaccin
immunotherapi
deliveri
specif
design
featur
may
advantag
depend
specif
cargo
deliv
one
way
selfassembl
har
along
line
function
surfac
reproduc
defin
physic
arrang
molecular
speci
approach
involv
immobil
antibodi
specif
recogn
key
protein
enzym
nucleic
acid
sequenc
known
biomark
diseas
exampl
antibodi
enzym
upregul
prostat
cancer
prostatespecif
antigen
psa
use
design
electrochem
sensor
antibodi
consist
two
compon
constant
region
conserv
across
antibodi
fc
variabl
fab
region
give
antibodi
exquisit
specif
bind
particular
molecul
thu
sensor
construct
involv
selfassembl
linker
molecul
onto
surfac
follow
chemic
conjug
fcbind
domain
linker
approach
result
wellord
local
antibodi
surfac
left
domain
bind
select
psa
avail
interact
sampl
sensor
provid
high
specif
sensit
detect
rare
psa
antigen
human
serum
accomplish
without
fluoresc
label
amplifi
signal
common
current
approach
detect
biomark
anoth
studi
selfassembl
use
local
antibodi
known
antigen
influenza
particular
orient
surfac
studi
le
brun
colleagu
design
system
engin
protein
protein
g
cell
wallassoci
protein
deriv
streptococcusi
selfassembl
onto
gold
surfac
adsorpt
mediat
thiol
function
group
importantli
engin
protein
g
preferenti
bind
fc
region
antibodi
affin
two
order
magnitud
higher
bind
fab
region
facilit
captur
antibodi
surfac
via
fc
region
featur
allow
variabl
regionswhich
conserv
conform
display
hiv
antigen
nanoparticl
surfac
promot
high
affin
bind
antibodi
structur
model
selfassembl
nanoparticl
nm
diamet
display
trimer
hiv
antigen
surfac
ferritin
core
indic
gray
three
monom
make
trimer
deriv
region
glycoprotein
indic
green
cyan
orang
b
bind
affin
free
monom
left
compar
nanoparticl
display
trimer
right
shown
bind
antibodi
detect
either
monom
trimer
form
antibodi
detect
express
correct
trimer
format
assess
dissoci
constant
k
bind
assay
report
except
monom
bind
bottom
left
antibodi
expectedli
exhibit
bind
affin
monom
form
adapt
permiss
bind
specif
case
nucleoprotein
influenzato
orient
away
surfac
remain
free
bind
antigen
one
advantag
design
maxim
number
avail
influenzaspecif
bind
site
ie
two
per
antibodi
assembl
mediat
conserv
fc
region
antibodi
specif
altern
influenza
antigen
antigen
pathogen
also
easili
exchang
platform
without
chang
basic
architectur
system
approach
demonstr
advantag
surfac
immobil
detect
mani
platformsboth
driven
selfassembl
govern
differ
type
interact
chemic
conjugationhav
limit
exampl
link
molecul
surfac
alter
physic
conform
result
capac
bind
antigen
molecul
interest
addit
increas
densiti
detect
molecul
eg
antibodi
surfac
may
offer
bind
site
high
pack
densiti
also
result
steric
hindranc
bind
thu
studi
explor
selfassembl
integr
linker
structur
provid
high
densiti
arrang
molecul
predict
orient
space
surfac
one
report
selfassembl
coiledcoil
peptid
structur
use
display
glycopeptid
found
surfac
potent
biolog
toxin
control
high
densiti
strategi
led
higher
avid
detect
antibodi
enhanc
sensit
assay
compar
direct
display
ie
without
selfassembl
nucleic
acid
provid
uniqu
platform
design
wellcontrol
structur
could
use
link
detect
probe
surfac
inher
control
sequenc
length
composit
exploit
drive
spontan
hierarch
assembl
one
recent
illustr
idea
involv
engin
singl
strand
dna
sequenc
spontan
assembl
dna
tetrahedron
structur
probe
tsp
probe
link
three
side
glass
substrat
unbound
free
side
tetrahedron
use
display
probe
differ
class
target
molecul
includ
nucleic
acid
protein
small
molecul
author
test
role
design
compar
sensit
purifi
dnatarget
structur
tsp
monom
three
control
probe
free
form
ie
tetrahedronfre
ssdna
ii
unpurifi
product
selfassembl
unpurifi
tsp
iii
purifi
structur
unrel
target
structur
tsp
polym
fig
equival
dose
dna
probe
conjug
glass
substrat
test
control
format
describ
complementari
structur
label
fluorophor
incub
group
follow
wash
step
remov
unbound
fluoresc
probe
dramat
signal
enhanc
use
tsp
monom
formul
observ
qualit
fluoresc
microscopi
fig
quantit
fluoresc
intens
fig
tsp
monom
exhibit
increas
signal
intens
compar
free
ssdna
well
enhanc
signal
level
compar
unpurifi
unrel
control
structur
describ
find
support
author
hypothesi
orient
conjug
selfassembl
respons
regular
space
molecul
substrat
author
also
demonstr
potenti
immobil
multipl
class
molecul
support
flexibl
diagnost
tool
futur
studi
modular
natur
platform
could
exploit
control
distanc
ligand
exampl
increas
decreas
length
dna
tetrahedron
chain
extens
footprint
selfassembl
structur
contrast
approach
use
altern
strategi
direct
conjug
molecul
surfac
may
gener
precis
control
total
ligand
bound
might
offer
level
control
space
physic
arrang
ligand
applic
selfassembl
enabl
surfacebound
display
well
control
space
valenc
antigen
could
also
extend
design
new
strategi
deliv
immun
cue
vivo
discuss
section
selfassembl
system
creat
design
guidelin
new
vaccin
immunotherapi
strategi
physiochem
properti
selfassembl
materi
help
determin
magnitud
natur
immun
respons
selfassembl
nanoand
microscal
materi
use
platform
explor
relationship
physic
engin
selfassembl
dna
structur
enhanc
sensit
immunosens
platform
schemat
depict
physic
arrang
tetrahedron
structur
probe
tsp
monom
compar
three
control
singl
strand
dna
ssdna
probe
free
form
ii
unpurifi
heterogen
tsp
product
iii
polymer
tsp
product
case
complementari
dna
sequenc
link
fluoresc
report
depict
pink
ad
show
expect
degre
orient
bind
test
sensit
probe
conform
uniform
quantiti
captur
probe
four
formul
depict
deposit
glass
substrat
equival
mass
detect
probe
ad
well
incub
period
excess
unbound
probe
wash
away
level
fluoresc
signal
detect
could
visual
qualit
fluoresc
microscopi
b
well
determin
quantit
c
adapt
permiss
chemic
characterist
materi
magnitud
natur
respons
elicit
exampl
role
particl
size
shape
studi
compar
spheric
formul
higher
aspect
ratio
conform
rod
filament
one
intrigu
theme
area
develop
materi
mimic
size
shape
pathogen
nanoscal
spheric
particl
repres
virus
anisotrop
shape
repres
bacteria
goal
investig
whether
properti
impact
immunogen
interact
immun
cell
exampl
scott
lab
demonstr
size
shape
particl
impact
associ
materi
target
apc
popul
dc
follow
intraven
inject
mice
materi
studi
selfassembl
via
hydrophob
interact
use
copolym
poli
ethylen
glycol
blpoli
propylen
sulfid
enabl
studi
differ
particl
geometri
fix
composit
conserv
surfac
chemistri
find
reveal
enhanc
uptak
spheric
particl
nm
diamet
dc
compar
smaller
nanoparticl
nm
diamet
latter
instead
found
associ
highli
macrophag
liver
contrast
fibrou
structur
form
polym
term
filomicel
remain
associ
phagocyt
cell
popul
blood
time
suggest
increas
circul
time
decreas
uptak
phagocyt
cell
togeth
result
indic
shape
size
selfassembl
particl
alter
biodistribut
retent
nanomateri
featur
guidelin
could
har
translat
applic
target
particular
subset
cell
addit
size
shape
surfac
properti
selfassembl
carrier
investig
one
recent
find
use
platform
gener
nanofibril
peptid
monom
selfassembl
format
betasheet
fibril
use
display
defin
concentr
combin
peptid
antigen
surfac
investig
role
fibril
properti
promot
proinflammatori
respons
fibril
neg
zeta
potenti
measur
surfac
charg
found
exhibit
significantli
reduc
even
undetect
cell
b
cell
ie
antibodi
respons
contrast
fibril
formul
contain
equival
dose
common
model
peptid
antigen
deriv
chicken
ovalbumin
ova
siinfekl
posit
charg
drove
potent
expans
antigenspecif
b
cell
respons
find
could
use
inform
design
criteriafor
selfassembl
materi
well
biomaterialsbas
approach
gener
exampl
translat
applic
strong
proinflammatori
respons
desir
eg
infecti
diseas
cancer
immunotherapi
design
nanomateri
posit
surfac
charg
may
help
tune
potenc
effect
immun
respons
import
exampl
proinflammatori
signal
garner
interest
clinic
adjuv
agent
design
amplifi
magnitud
immun
respons
current
clinic
adjuv
includ
potassium
aluminum
sulfat
alum
aluminum
hydroxid
mycophenol
acid
mpl
howev
mechan
action
adjuv
fullyunderstood
offer
limit
control
natur
respons
elicit
motiv
explor
signal
still
drive
enhanc
immunogen
definit
molecular
specif
discuss
section
apc
evolv
detect
molecular
signatur
pathogen
pattern
recognit
receptor
toll
like
receptor
tlr
detect
molecul
structur
present
mammalian
cell
ie
self
common
among
bacteria
virus
agonist
ligand
receptorssuch
lipoprotein
compon
bacteri
cell
wall
distinct
nucleic
acid
structur
frequent
viruseshav
emerg
promis
stimulatori
immun
cue
enhanc
immunogen
candid
vaccin
tlr
agonist
tlra
wellsuit
function
trigger
defin
molecular
pathway
upregul
express
activ
marker
apc
signal
drive
inflammatori
cytokin
secret
signal
promot
expans
proinflammatori
cell
trigger
potent
antibodi
respons
gener
nucleic
acid
intrigu
molecular
build
block
owe
abil
design
predict
structur
dna
rna
fortuit
number
nucleic
acid
class
also
activ
tlr
thu
selfassembl
field
molecular
tlr
agonist
great
interest
studi
investig
shape
carrier
use
deliv
tlr
ligand
tunabl
surfac
display
tlr
ligand
impact
degre
dc
activ
cytokin
secret
profil
discuss
section
dna
sequenc
fine
tune
form
defin
structur
enabl
control
organ
space
tertiari
featur
exampl
dendrim
assembl
control
load
ligand
cpg
nanoassembl
trigger
secret
inflammatori
cytokin
anoth
exampl
cpg
integr
helic
dna
assembl
form
differ
shape
includ
triangl
squar
polygon
assembl
structur
increas
number
side
carrier
enabl
increas
load
cpg
per
assembl
control
cpg
assembl
result
dose
directli
correl
level
inflamm
measur
incub
macrophag
cell
line
strategi
two
exampl
biomaterialsbas
approach
deliv
cpg
tlr
demonstr
potenti
predict
wellcontrol
selfassembl
nucleic
acid
design
immunogen
materi
anoth
exampl
modul
immunogen
nucleic
acid
deliveri
lynn
et
al
control
conform
tlra
tune
display
small
molecul
agonist
tlr
n
methacrylamid
hpma
polym
scaffold
fig
mass
per
mass
polym
increas
spontan
selfassembl
conjug
polym
observ
interestingli
equival
dose
administ
either
low
densiti
formul
exist
primarili
small
individu
polym
coil
fig
high
densiti
formul
assembl
polym
particl
fig
result
respons
differ
deliveri
particul
form
mice
drove
significantli
increas
level
key
inflammatori
cytokin
involv
expans
proinflammatori
cell
compar
equival
dose
small
polym
coil
form
fig
observ
accompani
increas
level
fluorescentlylabel
present
drain
ln
mice
treat
particul
form
compar
small
molecul
formul
sm
polym
coil
form
fig
ln
key
site
interact
apc
lymphocyt
crucial
target
candid
vaccin
immunotherapi
thu
mani
strategi
focu
design
carrier
drain
site
carri
ln
encount
apc
directli
access
tissu
target
introduct
solubl
biomaterialsbas
formul
exampl
lynn
et
al
use
librari
candid
materi
interrog
role
carrier
properti
modul
biodistribut
signal
magnitud
respons
previou
section
demonstr
advantag
selfassembl
adjuv
deliveri
pars
role
physicochem
featur
carrier
magnitud
natur
respons
elicit
section
focus
antigen
way
selfassembl
exploit
link
immun
outcom
antigen
physic
arrang
combin
rel
dose
discuss
vlp
see
section
motiv
goal
although
vlp
replic
high
densiti
antigen
display
physic
conform
target
pathogen
modif
amino
acid
sequenc
compris
vlpsto
exampl
integr
differ
antigen
interest
carriercan
impair
nanoparticl
format
chang
may
interfer
inhibit
noncoval
interact
typic
drive
uniform
selfassembl
thu
altern
strategi
condens
defin
fig
fibril
peptid
monom
enabl
coassembl
multipl
protein
tight
control
rel
dose
schemat
polypeptid
nanofib
selfassembl
fibril
peptid
sequenc
display
combin
protein
shown
red
green
blue
b
tunabl
incorpor
three
protein
gfp
dsred
egfp
demonstr
match
predict
actual
colour
valu
selfassembl
nanofib
assembl
microgel
indic
combin
protein
ligand
predict
colour
valu
determin
use
protein
mole
ratio
rgb
pixel
ratio
one
case
mutat
incorpor
disrupt
selfassembl
process
result
microgel
expectedli
match
predict
colour
valu
scale
bar
adapt
permiss
peptid
antigen
high
densiti
wellcontrol
physic
organ
could
mimic
key
featur
vlp
enabl
flexibl
platform
vaccin
immunotherapi
deliveri
along
line
collier
lab
use
nanofibril
deliv
control
combin
dose
densiti
antigen
betasheetform
peptid
sequenc
eg
link
peptid
protein
interest
follow
selfassembl
hydrogen
bond
interact
antigen
display
surfac
fibril
structur
fig
fiber
shown
drive
robust
antibodi
ie
b
cell
respons
model
antigen
deriv
ova
compar
antigen
free
form
intriguingli
expans
ovaspecif
antibodi
trigger
fibril
without
addit
explicit
adjuv
immunostimulatori
signal
properti
particular
interest
despit
excel
safeti
profil
import
success
clinicallyus
vaccin
mechan
convent
adjuv
eg
aluminum
salt
emuls
fulli
understood
nanofibril
platform
salient
exampl
approach
enabl
tunabl
incorpor
cue
rel
dose
multipl
protein
singl
batch
precis
control
demonstr
characterist
three
protein
distinct
fluorophor
incorpor
fibril
tunabl
ratio
could
individu
visual
fig
beyond
report
protein
new
work
also
explor
defin
antigen
display
properti
use
peptid
antigen
sequenc
staphylococcu
aureu
recogn
b
cell
cell
ii
peptid
sequenc
bind
mhcii
molecul
express
surfac
cell
mice
term
padr
defin
combin
concentr
sequenc
incorpor
fibril
fig
top
could
visual
transmiss
electron
microscopi
tem
fig
bottom
author
demonstr
codeliveri
sequenc
nanofib
drove
enhanc
antibodi
product
compar
equival
dose
peptid
sequenc
deliv
mixtur
nanofib
incorpor
peptid
separ
fig
hypothes
mechan
action
coincorpor
sequenc
promot
codeliveri
peptid
singl
b
cell
next
dose
b
cell
sequenc
fix
dose
padr
peptid
introduc
titrat
inject
mice
number
padrespecif
cell
found
depend
amount
padr
assembl
nanofibril
fig
natur
phenotyp
specif
cell
character
stain
transcript
factor
characterist
three
helper
cell
type
follicular
helper
tfh
type
helper
type
helper
fig
interestingli
dosedepend
polar
observ
higher
dose
padr
promot
tfh
cell
enhanc
magnitud
antibodi
respons
cell
promot
cellmedi
immun
thu
find
could
har
program
specif
phenotyp
immun
respons
exampl
promot
antibodi
product
combat
extracellular
bacteria
ie
tfh
promot
effector
cell
respons
eg
cancer
immunotherapi
addit
nanofib
approach
research
use
altern
selfassembl
strategi
control
antigen
deliveri
exampl
antigen
link
hydrophob
peptid
sequenc
assembl
coiledcoil
domain
condens
spheric
nanoparticl
report
focu
coiledcoil
domain
fold
nanoparticl
tunabl
ligand
display
size
control
paramet
ph
salt
concentr
fold
synthet
polym
poli
hydroxyethyl
methacryl
phema
contain
hydrophob
side
chain
drive
selfassemblyha
also
use
complex
condens
protein
antigen
nanoparticl
size
tune
control
concentr
protein
incorpor
parallel
synthet
peptid
amphiphil
design
gener
fiber
micel
structur
instanc
tirrel
group
demonstr
peptid
amphiphilebas
nanofib
assembl
hydrophob
interact
drive
cell
respons
model
epitop
siinfekl
enhanc
surviv
subcutan
melanoma
model
express
model
antigen
togeth
strategi
section
demonstr
potenti
incorpor
defin
combin
peptid
antigen
selfassembl
nanoor
microscal
materi
characterist
could
prove
particularli
advantag
context
pathogen
diseas
exhibit
nonuniform
heterogen
characterist
within
across
patient
perspect
elicit
respons
multipl
antigen
simultan
could
enhanc
protect
capac
prophylact
vaccin
efficaci
immunotherapi
two
current
clinic
exampl
includ
influenzawhich
undergo
rapid
mutat
result
new
formul
flu
vaccin
requir
yearand
cancer
tumor
associ
antigen
vari
greatli
patient
patient
within
given
tumor
time
final
consider
immunostimulatori
activ
synthet
vlp
see
section
selfassembl
structur
multival
deliveri
antigen
see
section
demonstr
without
inclus
explicit
adjuv
preclin
studi
intrins
stimulatori
characterist
signific
advantag
proinflammatori
applic
howev
formul
explor
enabl
present
antigen
without
trigger
strong
inflammatori
respons
fig
defin
nanoarchitectur
allow
direct
interrog
role
b
cell
epitop
codeliveri
rel
dose
shape
natur
immun
respons
schemat
depict
nanofib
selfassembl
fibril
domain
coincorpor
b
cell
peptid
sequenc
cell
peptid
visual
transmiss
electron
microscopi
bottom
b
potenti
either
fiber
codeliv
epitop
mixtur
fiber
individu
incorpor
cell
b
cell
peptid
rais
b
cell
respons
assess
measur
antibodi
titer
day
inject
mice
c
respons
fiber
coincorpor
fix
dose
b
cell
peptid
titrat
dose
cell
peptid
padr
character
number
padrespecif
cell
number
padrespecif
cell
exhibit
follicular
helper
tfh
helper
helper
phenotyp
quantifi
report
normal
maximum
valu
subset
adapt
permiss
could
instead
har
altern
applic
promot
toler
self
antigen
autoimmun
diseas
exampl
shen
colleagu
induc
toler
preclin
model
rheumatoid
arthriti
har
mechan
sever
acut
respiratori
syndrom
sar
viru
use
evad
immun
surveil
thu
rationallyassembl
structur
could
inform
design
therapi
either
proinflammatori
tolerogen
target
describ
detail
section
previou
two
section
focus
carrier
properti
deliveri
either
antigen
adjuv
alon
vaccin
immunotherapi
often
deliv
antigen
along
adjuv
modulatori
cue
direct
respons
antigen
central
paradigm
vaccin
infecti
diseas
also
develop
area
cancer
immunotherapi
tumorassoci
antigen
deliv
molecular
adjuv
eg
tlra
antibodi
therapeut
cancer
vaccin
regimen
codeliveri
antigen
one
multipl
tlra
could
enhanc
inflammatori
signal
cascad
antigen
present
promot
expans
antigenspecif
cell
proinflammatori
phenotyp
cell
eg
contrast
context
autoimmun
emerg
goal
deliveri
self
antigen
regulatori
immun
cue
induc
tolerogen
cell
phenotyp
regulatori
cell
reg
either
case
principl
codeliveri
antigen
immunomodulatori
signal
present
fundament
challeng
coordin
deliveri
multipl
signal
target
cell
tissu
vivo
hurdl
compound
dispar
physiochem
properti
eg
molecular
weight
charg
cargo
result
differ
biodistribut
traffick
inject
section
describ
strategi
exploit
uniqu
characterist
selfassembl
materi
codeliv
immun
signal
sever
approach
emerg
coassembl
codeliv
antigen
adjuv
use
noncoval
interact
includ
electrostat
hydrophob
interact
drive
forc
exampl
micel
particul
strategi
use
deliv
model
antigen
either
individu
tlra
defin
combin
tlr
interestingli
one
exampl
approach
demonstr
coincorpor
antigen
adjuv
enhanc
potenc
respons
minim
system
inflamm
offtarget
side
effect
often
associ
adjuv
deliveri
result
highlight
advantag
assembl
enabl
coencapsul
simpl
mixtur
offer
control
signal
distribut
follow
inject
gener
advantag
particulatebas
system
codeliveri
immun
cue
potenti
target
apc
evolv
detect
engulf
particul
function
offer
opportun
tune
uptak
process
antigen
use
control
architectur
selfassembl
materi
discuss
section
extracellular
exogen
antigen
typic
process
present
mhcii
pathway
lead
helper
cell
respons
yet
mani
applic
expand
cell
antigen
interest
critic
goal
thu
strategi
direct
process
present
deliv
antigen
toward
mhci
pathwaytyp
reserv
intracellular
peptid
form
degrad
viral
particl
infect
host
cellsar
key
interest
apc
engulf
pathogen
particl
materi
gener
entrap
endosom
lysosom
compart
pathway
trigger
present
antigen
along
mhcii
pathway
commun
cell
adapt
immun
system
extracellular
foreign
peptid
detect
howev
pathogen
requir
cytotox
cell
activ
destroy
infect
cell
antigen
must
reach
cytosol
cell
enabl
present
mhci
pathway
process
present
endocytos
antigen
present
cytosol
mhc
pathway
term
crosspresent
support
process
use
synthet
materi
swartz
hubbel
group
report
selfassembl
polymersom
oxid
sensit
assembl
load
immun
signal
deliveri
cell
promot
endosom
escap
cytosol
deliveri
antigen
ligand
anoth
exampl
ph
sensit
micel
selfassembl
hydrophob
interact
among
polym
carrier
use
studi
intracellular
antigen
traffick
promot
crosspresent
model
antigen
ova
nanoparticl
condens
hydrophob
interact
use
entrap
ova
cpg
ph
sensit
polym
poli
propylacryl
acid
assembl
exhibit
phdepend
membran
disrupt
properti
result
enhanc
present
ova
mhci
pathway
compar
simpl
mixtur
ova
peptid
polym
nanoparticl
togeth
result
highlight
opportun
design
selfassembl
carrier
target
apc
respons
environment
cue
control
immunolog
cargo
traffick
intracellular
compon
one
drive
forc
noncoval
selfassembl
emerg
approach
organ
immun
cue
wellcontrol
assembl
electrostat
interact
strategi
particularli
wellsuit
immunolog
applic
mani
immun
signal
interest
inher
charg
exampl
nucleic
acid
ligand
tlr
serv
immunostimulatori
cargo
facilit
selfassembl
neg
charg
phosphat
backbon
addit
peptid
antigen
exhibit
intrins
charg
amino
acid
side
chain
peptid
antigen
link
charg
amino
acid
sequenc
alter
charg
ratio
properti
exploit
drive
spontan
eg
complex
sequenti
eg
layerbylay
adsorpt
cargo
one
exampl
layerbylay
assembl
use
coassembl
codeliv
cell
antigen
b
cell
antigen
cancer
model
antigen
modifi
lysin
residu
confer
posit
charg
facilit
electrostat
associ
synthet
anion
polym
acid
selfassembl
particl
drove
signific
increas
antibodi
titer
control
formul
without
lysin
modif
exhibit
significantli
diminish
respons
result
demonstr
import
cation
modif
drive
electrostat
selfassembl
underscor
synergist
effect
observ
multipl
antigen
codeliv
consist
enhanc
effect
upon
codeliveri
b
cell
antigen
singl
nanofib
describ
section
approach
synthet
polym
exploit
coassembl
antigen
tlr
agonist
via
electrostat
assembl
de
geest
et
al
report
polyelectrolyt
multilay
strategi
codeliv
antigen
tlr
agonist
microcapsul
exampl
ova
precipit
calcium
carbon
core
coat
layerbylay
fashion
two
synthet
polyelectrolyt
polylarginin
dextran
sulfat
case
final
layer
cpg
ad
capsul
drove
signific
expans
transgen
cell
receptor
specif
ova
peptid
well
secret
proinflammatori
cytokin
among
cell
mice
assembl
capsul
drove
dramat
increas
inflammatori
cytokin
secret
among
cell
subset
enhanc
level
antibodi
product
compar
solubl
ova
solubl
mixtur
ova
cpg
capsul
encapsul
ova
result
support
synergist
effect
codeliveri
antigen
adjuv
enabl
electrostaticallydriven
coassembl
lab
recent
report
platform
coassembl
antigen
adjuv
nanostructur
materi
construct
entir
immun
signal
immun
polyelectrolyt
multilay
ipem
built
use
electrostat
layerbylay
process
hallmark
pem
yet
uniqu
mimic
attract
featur
biomateri
elimin
polym
matric
carrier
approach
simplifi
composit
provid
modular
high
absolut
cargo
load
also
elimin
intrins
carrier
effect
ipem
assembl
gold
nanoparticl
use
form
carrierfre
hollow
microcapsul
coat
microneedl
array
form
capsul
model
antigen
siinfekl
link
cation
arginin
residu
confer
posit
charg
assembl
inher
anion
nucleic
acidbas
agonist
polyic
thu
cargo
antigen
adjuv
serv
function
immun
signal
structur
compon
enabl
electrostat
assembl
format
ipem
capsul
upon
core
remov
fig
layerbylay
assembl
enabl
control
load
function
number
bilay
deposit
fig
compar
equival
vaccin
compos
mixtur
antigen
adjuv
compon
assembl
ipem
dramat
enhanc
expans
antigenspecif
cell
indic
increas
frequenc
siinspecif
cell
prime
boost
inject
fig
increas
correl
prolong
surviv
vaccin
mice
challeng
melanoma
express
siinfekl
antigen
fig
flexibl
platform
cancer
vaccin
demonstr
use
microneedl
array
substrat
assembl
ipem
compos
cpg
tumor
antigen
fig
array
enabl
codeliveri
signal
skin
mice
fig
drove
signific
expans
tumorspecif
cell
follow
applic
coat
array
fig
togeth
exampl
demonstr
potenti
ipem
platform
coloc
immun
signal
multipl
lengthscal
without
inclus
synthet
polym
carrier
compon
simplic
modulatori
could
support
design
welldefin
vaccin
formul
facilit
character
ultim
translat
vaccin
immunotherapi
fig
tunabl
electrostaticallydriven
assembl
antigen
adjuv
carrierfre
assembl
schemat
layerbylay
assembl
antigen
adjuv
form
carrierfre
immun
polyelectrolyt
multilay
ipem
capsul
b
tunabl
load
fluoresc
antigen
adjuv
ipem
function
number
bilay
deposit
microparticl
core
c
expans
antigenspecif
ie
siinspecif
cell
follow
two
administr
ipem
compar
frequenc
untreat
mice
mice
given
simpl
mixtur
antigen
adjuv
surviv
mice
follow
challeng
model
melanoma
e
microneedl
coat
melanoma
antigen
agonist
cpg
f
deliveri
signal
skin
mice
follow
microneedl
applic
g
expans
cell
follow
two
applic
coat
microneedl
mn
indic
red
arrow
panel
ad
adapt
panel
eg
adapt
permiss
preclin
studi
use
selfassembl
materi
demonstr
excit
translat
potenti
infect
diseas
model
new
vaccin
immunotherapi
face
challeng
perform
product
work
describ
section
begin
reveal
design
rule
selfassembl
materi
interact
immun
cell
section
focus
translat
compon
selfassembl
present
recent
exampl
involv
preclin
model
target
current
clinic
challeng
exampl
fundament
issu
develop
new
vaccin
immunotherapi
balanc
efficaci
safeti
one
extrem
deliveri
live
virus
bacteria
trigger
strong
protect
immun
respons
increas
risk
infect
patient
contrast
small
subunit
pathogen
eg
short
peptid
monom
confer
less
risk
also
less
immunogen
characterist
may
result
suboptim
inadequ
respons
necessit
multipl
dose
addit
adjuv
amplifi
respons
complic
composit
character
formul
caus
advers
reaction
tradit
vaccin
incorpor
live
attenu
inactiv
eg
heatkil
pathogen
often
codeliv
adjuv
balanc
two
factor
howev
approach
requir
avail
pathogen
larg
quantiti
manufactur
recent
develop
season
influenza
vaccin
also
reflect
critic
challeng
associ
prophylact
vaccin
manufactur
distribut
two
gener
vaccin
influenza
approv
first
inject
vaccin
formul
compos
inactiv
viru
second
live
attenu
viru
deliv
intranas
recent
studi
evalu
vaccin
effect
children
age
conduct
center
diseas
control
prevent
cdc
reveal
nasal
spray
formul
exhibit
reduc
efficaci
compar
inject
formul
vaccin
result
led
cdc
advisori
committe
immun
practic
vote
nasal
spray
formul
use
season
addit
despit
reliabl
level
protect
immun
confer
mani
vaccinesinclud
flu
still
signific
improv
opportun
case
current
vaccin
primarili
gener
grow
viru
chicken
egg
inevit
take
time
gener
larg
scale
estim
week
timelin
produc
contrast
cell
culturebas
approach
may
requir
roughli
half
durat
produc
delay
approach
particularli
relev
exampl
season
influenza
vaccin
formul
must
chang
year
reflect
strain
like
spread
thu
strategi
would
allow
rapid
econom
product
well
flexibl
incorpor
antigen
one
target
strain
viru
could
transform
incorpor
live
attenu
viru
mention
still
pose
risk
infect
motiv
explor
synthet
approachesperhap
incorpor
selfassemblyto
recapitul
structur
pathogen
potenti
replic
anoth
challeng
face
vaccin
stabil
illustr
one
recent
studi
storag
alum
clinicallyapprov
adjuv
month
led
signific
decreas
immunogen
result
exemplifi
hurdl
field
requir
cold
chain
refriger
order
dissemin
vaccin
immunotherapi
worldwid
current
clinic
option
typic
sensit
extrem
heat
cold
care
control
storag
requir
maintain
stabil
emulsionbas
adjuv
viabil
longterm
potenc
live
attenu
pathogen
limit
particularli
relev
critic
region
deliv
vaccin
develop
world
access
healthcar
profession
refriger
extrem
limit
selfassembl
alreadi
util
area
one
studi
confirm
selfassembl
nanostructur
display
peptid
epitop
mycobacterium
tuberculosi
maintain
immunogen
even
storag
month
compar
freshlyprepar
dose
one
exampl
selfassembl
weigh
specif
translat
focu
section
bring
translationallygear
report
forefront
illustr
new
selfassembl
strategi
either
promot
regul
respons
vaccin
immunotherapi
selfassembl
materi
gener
efficaci
respons
preclin
model
infect
cancer
one
recent
approach
minim
risk
maxim
efficaci
therapeut
context
use
vlpbase
vaccin
incorpor
deliv
influenza
antigen
potenti
vlp
protect
viral
challeng
strain
vlp
deriv
ie
homolog
strain
well
challeng
strain
test
importantli
potenti
protect
multipl
strain
could
help
determin
whether
candid
vaccin
therapi
potenti
confer
broad
protect
question
particularli
relev
influenza
viru
mutat
rapidli
evad
immun
clearanc
vlp
exhibit
demonstr
excit
preclin
clinic
success
consider
beyond
efficaci
product
recombin
protein
ie
vlp
cell
line
associ
high
cost
low
yield
requir
care
purif
character
ensur
homogen
reproduc
potenc
thu
ongo
studi
aim
enhanc
effici
yield
puriti
final
vaccin
product
parallel
research
also
investig
use
short
synthet
monom
simpler
produc
cell
cultur
compar
full
recombin
protein
could
enabl
cellculturefre
product
monom
could
har
incorpor
defin
target
antigen
nanoor
microscal
materi
selfassembl
nanofib
strategi
enabl
high
valenc
display
model
antigen
describ
section
also
har
elicit
respons
diseaserelev
antigen
exampl
platform
tirrel
lab
extend
immun
group
streptococcu
rudra
colleagu
demonstr
approach
trigger
antibodi
respons
malaria
antigen
drive
forc
selfassembl
latter
approachbetasheet
formationha
also
employ
incorpor
protein
envelop
west
nile
viru
eiii
work
selfassembl
peptid
contain
betasheetform
domain
spontan
form
inject
hydrogel
entrap
eiii
enabl
sustain
subcutan
deliveri
mice
hydrogel
formul
confer
signific
protect
viral
challeng
model
final
surviv
compar
untreat
mice
mice
treat
eiii
incorpor
clinic
adjuv
alum
exampl
discuss
repres
approach
use
selfassembl
gener
hydrogel
larger
dimens
macro
scale
along
line
other
develop
peptid
fiber
selfassembl
inject
mimic
antigen
depot
often
form
convent
emulsionbas
adjuv
goal
approach
gener
persist
sourc
antigen
prolong
immunostimul
partial
mechan
action
alum
current
adjuv
use
clinic
fiberbas
approach
employ
deliv
hepat
b
antigen
cpg
trigger
enhanc
humor
cellular
respons
compar
formul
contain
alum
equival
dose
eiii
togeth
result
support
potenti
use
selfassembl
materi
gener
vivo
depot
antigen
immunostimulatori
cue
enhanc
immunogen
approach
could
also
simplifi
depotlik
vaccin
formul
incorpor
welldefin
peptid
sequenc
rather
complex
adjuv
system
molecular
adjuv
deliv
selfassembl
system
also
explor
diseas
context
either
without
antigen
latter
case
strategi
often
exploit
fact
diseas
immun
system
activ
survey
process
diseaserelev
antigen
yet
respons
antigen
effect
gener
respons
combat
diseas
exampl
cancer
lymph
node
often
contain
tumor
associ
antigen
reach
site
either
passiv
drainag
lymphat
activ
transport
via
apc
howev
tumor
microenviron
often
highli
immunosuppress
evad
detect
clearanc
immun
system
cell
tumor
may
alter
express
key
surfac
marker
secret
regulatori
cytokin
suppress
tumorinfiltr
immun
cell
reduct
signal
signal
effect
reduc
level
danger
signal
inhibit
gener
robust
respons
need
clear
tumor
thu
incorpor
modulatori
signal
may
abl
redirect
skew
type
respons
gener
diseaserelev
antigen
one
exampl
approach
modul
respons
clinicallyrelev
context
incorpor
molecular
adjuv
selfassembl
materi
cpg
incorpor
multipl
selfassembl
nanoparticl
formul
noncoval
interact
lipid
gold
nanoparticl
synthet
polym
broadli
strategi
aim
enhanc
circul
time
well
target
cpg
target
cell
popul
apc
like
dendrit
cellsthrough
nanoparticlemedi
deliveri
approach
shown
slow
tumor
growth
enhanc
surviv
mous
model
melanoma
anoth
exampl
selfassembl
har
incorpor
multipl
tlra
nanoparticl
tumor
associ
antigen
mucin
transmembran
glycoprotein
nanoparticl
design
selfassembl
electrostat
interact
codeliv
three
therapeut
cargo
treatment
mice
nanoparticl
confer
synergist
effect
surviv
aggress
melanoma
model
compar
formul
contain
antigen
singl
adjuv
antigen
alon
fig
electrostat
complex
immun
signal
restrain
inflammatori
signal
autoimmun
schemat
depict
hypothes
mechan
moggpg
complex
typic
ms
selfantigen
mog
process
present
dc
presenc
excess
signal
drive
expans
selfantigenspecif
effector
cell
left
contrast
coadministr
self
mog
peptidemodifi
arginin
residu
confer
posit
charg
mogr
xwith
antagonist
ligand
gpg
could
blunt
inflammatori
signal
lead
develop
mogspecif
regulatori
cell
right
b
nanoscal
moggpg
complex
exhibit
tunabl
surfac
charg
function
input
ratio
mog
peptid
gpg
c
signal
assess
report
cell
line
follow
stimul
cell
cpg
addit
either
free
mogr
x
free
gpg
mogr
x
gpg
complex
investig
potenti
restrain
cpginduc
signal
prolifer
mogspecif
transgen
cell
follow
cocultur
splenic
dc
isol
wildtyp
mice
treat
cpg
either
free
mogr
x
mogr
x
gpg
complex
adapt
permiss
final
electrostat
assembl
approach
describ
section
also
exploit
proimmun
diseas
applic
exampl
condens
adjuv
antigen
either
cancer
viral
infect
de
geest
et
al
demonstr
dramat
enhanc
mous
surviv
use
layerbylay
assembl
capsul
deliv
antigen
compar
solubl
antigen
model
melanoma
modular
natur
pem
system
exploit
instead
incorpor
antigen
influenza
challeng
studi
pemmedi
deliveri
antigen
exhibit
enhanc
protect
effect
solubl
antigen
support
role
deliveri
antigen
selfassembl
particl
enhanc
protect
immun
effect
one
final
exampl
electrostat
assembl
proinflammatori
therapeut
applic
involv
use
layerbylay
assembl
codeliv
immun
signal
hiv
vaccin
administ
via
transderm
deliveri
irvin
lab
demonstr
approach
coat
microneedl
array
degrad
cation
polym
poli
layer
plasmid
dna
encod
hiv
antigen
polyic
anion
follow
microneedl
applic
coat
engin
releas
layer
detach
microneedl
substrat
remain
skin
codeliveri
signal
confirm
via
immunofluoresc
analysi
mous
skin
follow
microneedl
applic
persist
signal
site
administr
compar
intraderm
inject
site
ie
mous
ear
releas
film
microneedl
drove
potent
antigenspecif
cell
expans
enhanc
antibodi
titer
compar
intramuscular
intraderm
inject
final
skin
penetr
deliveri
immun
signal
demonstr
nonhuman
primat
skin
support
translat
potenti
approach
move
toward
human
diseas
applic
har
selfassembl
regul
immun
respons
promot
toler
autoimmun
transplant
discuss
earlier
autoimmun
diseas
self
antigen
incorrectli
recogn
trigger
inflammatori
attack
exampl
multipl
sclerosi
peptid
fragment
myelin
matrix
line
neuron
attack
deliveri
tolerogen
immun
signal
may
abl
redirect
immun
respons
selfantigen
skew
cell
differenti
away
inflammatori
phenotyp
toward
regulatori
phenotyp
howev
potenti
expand
therapeut
cell
type
regulatori
cell
involv
toler
activ
autoimmun
signific
hurdl
ms
autoimmun
diseas
character
excess
inflamm
develop
regulatori
cell
depend
potenti
apc
subsequ
lymphocyt
process
present
recogn
selfantigen
absenc
stimulatori
immun
cue
eg
signal
toward
goal
downregul
proimmun
signal
mellor
group
describ
electrostat
condens
plasmid
dna
promot
tolerogen
immun
function
nucleic
acid
fig
carrierfre
coloc
selfantigen
regul
promot
toler
mous
cell
mous
model
autoimmun
sampl
human
patient
schemat
carrierfre
ipem
capsul
formul
antagonist
ligand
gpg
myelin
selfantigen
modifi
three
arginin
residu
mogr
b
ipem
exhibit
tunabl
rel
load
cargo
function
cargo
input
synthesi
process
c
secret
inflammatori
cytokin
cocultur
prepar
isol
wildtyp
splenic
dc
mice
incub
media
alon
solubl
cpg
alon
cpg
either
solubl
gpg
solubl
control
oligonucleotid
regul
signal
ctrl
ipem
assembl
mogr
gpg
mogr
gpg
mogr
ctrl
free
mogr
overnight
cultur
mogspecif
cell
isol
transgen
mice
ad
cultur
allow
incub
three
day
supernat
analyz
elisa
subset
cocultur
sampl
describ
c
analyz
express
marker
regulatori
cell
flow
cytometri
e
mice
induc
model
multipl
sclerosi
eae
either
left
untreat
administ
two
dose
mogr
gpg
ipem
day
post
induct
sever
diseaseinduc
paralysi
assess
use
clinic
score
scale
f
peripher
blood
mononuclear
cell
human
ms
patient
incub
media
alon
mogr
gpg
ipem
mogr
ctrl
ipem
metabol
activ
measur
use
mtt
assay
g
supernat
cultur
f
analyz
secret
inflammatori
use
luminex
assay
adapt
permiss
cargo
target
stimul
ifn
gene
sting
pathway
respons
produc
cytokin
potenti
inflamm
nucleic
acid
condens
electrostat
assembl
common
polyc
polyethyenimin
pei
form
polyplex
design
enhanc
gene
deliveri
test
therapeut
potenti
approach
dna
condens
np
form
dnp
test
wellcharacter
mous
model
multipl
sclerosi
ms
experiment
autoimmun
encephalomyel
eae
model
mice
inject
mog
peptid
emulsifi
strong
proinflammatori
signal
complet
freund
adjuv
cfa
follow
administr
pertussi
toxin
serv
adjuv
open
bloodbrainbarri
proinflammatori
mogspecif
cell
abl
migrat
central
nervou
system
ie
spinal
cord
brain
recogn
attack
myelin
result
attack
progress
paralysi
develop
week
studi
signific
decreas
mean
clinic
score
ie
reduc
diseaseinduc
paralysi
observ
treatment
dnp
compar
vehicl
control
treatment
regimen
effect
observ
treatment
initi
either
time
diseas
induct
fig
onset
diseas
symptom
fig
dnp
shown
restrain
secret
numer
inflammatori
cytokin
implic
diseas
fig
importantli
restraint
diseas
depend
deliveri
dna
cargo
np
format
match
solubl
dose
caus
effect
support
role
selfassembl
enhanc
deliveri
therapeut
immun
cargo
vivo
intrigu
recent
idea
employ
biomateri
codeliv
selfantigen
regulatori
immun
cue
promot
expans
cell
selfantigenspecif
exert
tolerogen
regulatori
function
instead
inflammatori
attack
idea
underpin
part
fascin
new
role
tlr
signal
autoimmun
diseas
recent
studi
reveal
excess
signal
tlr
contribut
pathogenesi
autoimmun
mous
model
human
patient
work
steinman
lab
demonstr
potenti
antagonist
ligand
gpg
partial
restrain
inflamm
reduc
sever
symptom
eae
mice
administ
solubl
form
lab
hypothes
codeliveri
myelin
selfantigen
electrostat
assembl
gpg
might
blunt
signal
present
multipl
sclerosi
skew
cell
respons
toward
reg
abl
control
diseas
fig
form
polyplexlik
structur
compos
gpg
signal
myelin
antigen
mog
conjug
one
two
arginin
residu
confer
posit
charg
mogr
mogr
respect
elimin
synthet
compon
vari
input
fig
schemat
represent
encapsul
small
molecul
immunomodul
tacrolimu
enzymedegrad
hydrogel
b
releas
kinet
tacrolimu
hydrogel
repres
incub
pb
presenc
enzym
drive
hydrogel
degrad
tacrolimuscontain
hydrogel
inject
subcutan
side
hind
limb
transplant
rat
model
control
treatment
includ
treatment
hydrogel
alon
vehicl
control
solubl
bolu
inject
tacrolimu
tacrolimu
hydrogel
inject
opposi
ie
contralater
side
hind
limb
transplant
graft
surviv
quantifi
c
could
assess
qualit
imag
compar
transplant
hind
limb
mous
treat
solubl
tacrolimu
tacrolimu
hydrogel
formul
b
adapt
permiss
cargo
electrostaticallydriven
selfassembl
lead
format
nanoscal
complex
nm
diamet
tunabl
properti
load
zeta
potenti
ie
surfac
charg
fig
mog
gpg
complex
shown
downregul
signalingth
target
ligand
gpg
cargo
fig
restrain
prolifer
antigenspecif
cell
use
cocultur
system
transgen
cell
specif
mog
peptid
fig
attenu
eae
parallel
adapt
ipem
platform
describ
section
promot
toler
assembl
gpg
myelin
selfantigen
fig
ipem
capsul
form
myelin
peptid
gpg
enabl
tunabl
absolut
rel
cargo
load
compon
fig
interestingli
moggpg
ipem
promot
antigenspecif
cell
prolifer
cocultur
system
mention
howev
expand
myelinreact
cell
found
secret
lower
level
inflammatori
cytokin
fig
higher
express
level
marker
characterist
reg
fig
compar
control
formul
incorpor
myelin
peptid
nucleotid
regul
signal
ctrl
fig
orang
bar
find
suggest
ipem
might
promot
expans
myelinspecif
reg
control
diseas
highli
specif
manner
rather
act
broad
immunosuppress
pathway
eae
model
ipem
found
protect
mice
onset
eae
symptom
fig
final
sampl
human
ms
patient
ipem
provid
similar
benefit
observ
primari
mous
cell
fig
ipem
contain
mog
either
gpg
ctrl
activ
cell
measur
increas
metabol
activ
fig
howev
ipem
contain
gpg
restrain
inflammatori
cytokin
secret
rel
ctrlcontain
ipem
fig
result
human
ms
patient
sampl
highlight
uniqu
opportun
regul
tlr
signal
impact
human
immun
cell
function
anoth
applic
interest
promot
immun
toler
transplant
follow
transplant
host
immun
system
often
recogn
graftth
cell
tissu
organ
transferreda
foreign
mount
attack
care
taken
ensur
donor
close
match
recipi
patient
administ
lifelong
regimen
potent
immunosuppress
drug
resist
graft
reject
leav
individu
immunocompromis
approach
gener
durabl
specif
transplant
toler
could
therefor
dramat
improv
patient
outcom
qualiti
life
mani
candid
drug
along
line
highli
hydrophob
small
molecul
use
amphiphil
carrier
lipid
polym
hydrophob
residu
allow
incorpor
hydrophob
moieti
ultim
easier
incorpor
aqueousbas
inject
formul
along
line
hydrophob
dexamethason
tacrolimu
incorpor
selfassembl
materi
promot
toler
control
inflamm
latter
exampl
hydrogel
approach
use
entrap
tacrolimu
macroscal
assembl
fig
approach
enabl
control
releas
encapsul
tacrolimu
trigger
degrad
hydrogel
presenc
enzym
eg
matrix
metalloproteas
fig
local
introduct
hydrogel
contain
tacrolimu
close
proxim
graft
hind
limb
transplant
model
dramat
improv
surviv
graft
surviv
day
posttranspl
fig
contrast
administr
formul
opposit
side
transplant
ie
contralater
promot
surviv
untreat
mice
mice
treat
singl
dose
solubl
tacrolimu
achiev
level
protect
local
deliveri
close
proxim
graft
exampl
underscor
opportun
har
selfassembl
target
local
deliveri
immunomodulatori
signal
key
tissu
translat
nanotechnolog
preclin
studi
human
use
seen
rel
littl
success
limit
spark
intens
interest
ration
design
nanosystem
provid
control
composit
wellcharacter
mechan
action
trigger
immun
respons
selfassembl
offer
uniqu
opportun
gener
simpl
welldefin
materi
precis
control
paramet
like
shape
size
valenc
charg
rel
absolut
load
cargo
discuss
potenti
har
design
new
immunosens
diagnost
tool
studi
fundament
interact
biomateri
immun
cell
interrog
link
physiochem
properti
immunogen
develop
selfassemblyen
therapeut
elicit
tunabl
immun
respons
critic
need
help
field
move
forward
greater
focu
use
clinicallyrelev
experiment
system
anim
model
comparison
exist
clinic
option
wellcharacter
preclin
nanomateri
formul
benchmark
also
help
improv
robust
consist
emerg
technolog
owe
complex
immun
respons
wide
spread
discuss
engin
immunologist
clinician
help
frame
research
goal
question
address
lastli
selfassembl
technolog
gener
biomateri
vaccin
immunotherapi
develop
consider
manufactur
regulatori
issu
need
consid
earli
even
promis
technolog
clinic
impact
feasibl
produc
character
despit
need
immun
engin
field
pois
make
real
impact
understand
role
materi
play
bias
innat
adapt
immun
function
enabl
new
immun
technolog
